Investing.com – U.K. equities were higher at the close on Wednesday, as gains in the Pharmaceuticals & Biotech, Banking and Media sectors propelled shares higher. At the close in London,...
European stocks were on the rebound, alongside Wall Street as investors went shopping for beaten down stocks after Tuesday's rout.
AstraZeneca Plc (NASDAQ: AZN) will take complete control of Caelum Biosciences in a deal worth up to $500 million, sharpening its focus on rare-disease drugs following its purchase...
Shares of airport and train station restaurant operator SSP Group stumbled on Wednesday after warning of a slightly slower recovery in sales in the current fiscal year.
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks Hitting 52-week Highs...
Fortress Biotech (FBIO) has added ~18.8% in the pre-market on the news of the impending acquisition of Caelum Biosciences, a clinical-stage biotechnology company it founded.According...
AstraZeneca’s (AZN) Alexion has exercised its option to acquire all remaining equity in Caelum Biosciences for CAEL-101, a fibril-reactive monoclonal antibody (mAb) for the...
The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved AstraZeneca plc’s (NASDAQ: AZN) Saphnelo (anifrolumab) for systemic lupus erythematosus (SLE), a serious autoimmune...
AstraZeneca’s (AZN) Saphnelo (anifrolumab) has been approved in Japan for the treatment of adult patients with systemic lupus erythematosus ((SLE)), a serious autoimmune...
A small-scale study of AstraZeneca Plc (NASDAQ: AZN) COVID-19 combined with Sputnik Light vaccines has shown robust antibody growth in most of the study's participants, citing the Russian...
London stocks cling to positive territory on Monday.
Need to Know: Will you be ready when growth stocks come roaring back?
Online delivery, social media apps and software are hot stocks for the growth fund manager who says value companies are about to take a back seat.
The FTSE 100 was an outperformer on Friday, but only just as Europe's stock markets were deep in the red.
According to a real-world study from Malaysia, Sinovac Biotech Ltd's (NASDAQ: SVA) COVID-19 vaccine, CoronaVac, showed effectiveness against serious illness. However, shots from Pfizer...
AstraZeneca Plc (NASDAQ: AZN) has reported high-level results from the PROpel Phase 3 trial of Lynparza (olaparib) in metastatic castration-resistant prostate cancer (mCRPC). The data showed...
AstraZeneca (AZN) announces positive results from Phase III PROPel trial evaluating Lynparza (olaparib) in combination with abiraterone, demonstrating meaningful improvement in...
By Dhirendra Tripathi Investing.com – Novavax stock (NASDAQ:NVAX) climbed 9% Thursday after the company applied with the World Health Organization for emergency approval to its...
AstraZeneca (AZN) has partnered with VaxEquity to commercialize drugs based on the self-amplifying RNA (saRNA) platform of the latter.Originated from Imperial College London, the...
RedHill Biopharma Ltd (NASDAQ: RDHL) has announced a settlement and license agreement with Aurobindo Pharma USA Inc resolving their patent litigation in the U.S. The litigation was related...
AstraZeneca Plc (NASDAQ: AZN) struck a deal with a startup for a self-amplifying RNA (saRNA) therapeutics platform developed at Imperial College London. Under the deal, VaxEquity could...
AstraZeneca has teamed up with a startup from Imperial College London to expand disease fighting beyond COVID-19 using next generation messenger RNA technology. That's according to the...
Refusal to recognise visitors as vaccinated unless they received their shots in a handful of select countries.
By Dhirendra Tripathi Investing.com – AstraZeneca (LON:AZN) ADRs (NASDAQ:AZN) traded 1% higher in Tuesday’s premarket as the proposed changes to rules governing travel to the U.S. will...
A spokesman for the European Union says that individuals who have been inoculated against COVID-19 with AstraZeneca's vaccine should be able to travel to the U.S.
AstraZeneca plc (NASDAQ: AZN) will invest $360 million to develop a manufacturing facility in Ireland to produce active pharmaceutical ingredients (APIs). The planned investment at the...
AstraZeneca (AZN) plans to invest $360M to establish a next-generation active pharmaceutical ingredient ((API)) manufacturing facility for small molecules near Dublin, Ireland.The...
Investing.com – U.K. equities were lower at the close on Monday, as losses in the Life Insurance/Assurance, Banking and Industrial Transportation sectors propelled shares lower. At the...
China's growing Evergrande crisis overshadows London markets. International Airlines Group soared on a report that U.S. travel restrictions will
The drug maker said Enhertu significantly reduced the risk of death or disease progression in women with advanced disease in a large clinical trial, the latest sign that its push into...
Metastatic breast cancer patients treated with AstraZeneca's Enhertu had a reduced risk of disease progression or death by 72% compared to Roche's Kadcyla.
Updated results from CASPIAN Phase III trial showed AstraZeneca’s (AZN) Imfinzi (durvalumab) in combination with a choice of chemotherapies, etoposide plus either carboplatin or...
Surface Oncology (SURF) shares have approached the highest level since July after AstraZeneca (AZN) showed favorable results for anti-CD73 monoclonal antibody oleclumab in...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
